Metal Complexes as Drugs and Chemotherapeutic Agents

Comprehensive Coordination Chemistry II

Volumn 9, Issue , 2004, Pages 809-840

  Farrell, N ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATION; DISEASES; ENZYME INHIBITION; INORGANIC COMPOUNDS; LIGANDS; MEDICAL PROBLEMS; METAL COMPLEXES; ZINC;

CENTRAL METALS; CHELATING AGENT; CHEMOTHERAPEUTIC AGENTS; CO-ORDINATION CHEMISTRIES; IMAGING AGENT; INORGANIC CHEMISTRY; KEY FEATURE; MECHANISM OF ACTION; METALS IONS; RADIOIMMUNOIMAGING;

METAL IONS;

EID: 84902429552     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-08-043748-6/09021-6     Document Type: Chapter

References (282)

1. Farrell N.P. Transition Metal Complexes as Drugs and Chemotherapeutic Agents 1989, 11. Reidel-Kluwer Academic Press, Dordrecht. B.R. James, R. Ugo (Eds.).
2. Farrell N.P. The Uses of Inorganic Chemistry in Medicine 1999, The Royal Society of Chemistry, Cambridge.
3. Orvig C., Abrams M.J. Chem. Rev. 1999, 99:2201-2204.
4. Guo Z., Sadler P.J. Angew Chem., Int. Ed. Engl. 1999, 38:1512-1531.
5. Keppler B. Metal Complexes in Cancer Chemotherapy 1993, VCH, Basel.
6. Clarke M.J. Progress in Clinical Biochemistry and Medicine 1989, 10.
7. Metal Complexes in Cancer Therapy 1994, 1:215. Chapman and Hall, London. S.P. Fricker (Ed.).
8. Berthon G. Handbook of Metal-ligand Interactions in Biological Fluids 1995, 1 and 2. Marcel-Dekker Inc., New York.
9. Metallopharmaceuticals I: DNA Interactions 1999, 1:1s99. Springer-Verlag, Berlin. M.J. Clarke, P.J. Sadler (Eds.).
10. Sadler P.J. Adv. Inorg. Chem. 1999, 49:183-306.
11. Roat R.M. Bioinorganic Chemistry 2002, A Short Course Wiley Interscience, Hoboken, New Jersey.
12. Metal Ions in Biological Systems 1995, 31. Marcel Dekker, New York. H. Sigel, A. Sigel (Eds.).
13. Coord. Chem. Rev. 2003, 232. Aspects of Biomedical Inorganic Chemistry, Elsevier Press. A.B.P. Lever (Ed.).
14. Martindale. The Extra Pharmacopoeia 1996, The Royal Pharmaceutical Society, London, Martindales Pharmacopeia. 31 sted. J.E.F. Reynolds (Ed.).
15. Andersen O. Chem. Rev. 1999, 99:2683-2710.
16. Liu Z.D., Hider R.C. Coord. Chem. Rev. 2002, 232:151-172.
17. Sarkar B. Chem. Rev. 1999, 99:2535-2544.
18. Whittaker M., Floyd C.D., Brown P., Gearing A.J. Chem. Rev. 1999, 99:2735-2776.
19. Parks W.C., Mecham R., Mecham R.P. Matrix Metalloproteinases 1998, Academic Press.
20. Vallee B.L., Auld D.S. Acc. Chem. Res. 1993, 26:543-551.
21. 1995, 259. Verlag, Basel. P. Jolles, H. Jornvall (Eds.).
22. Rein A., Henderson L.E., Levin J.G. Trends Biochem. Sci. 1998, 23:297-301.
23. Albert A. Selective Toxicity 1979, Wiley, New York. 6th ed.
24. Food and Drug Administration. United States Food and Drug Administration 2002, http://www.fda.gov.
25. National Cancer Institute. NCI-DTP 2002, http://nci.nih.gov/dtp.cfm.
26. Bertucci C., Domenici E. Curr. Med. Chem. 2002, 9:1463-1481.
27. He X.M., Carter D.C. Nature 1992, 358:209-215.
28. Chan J., Huang Z., Merrifield M.E., Salgado M.T., Stillman M.J. Studies of metal binding reactions in metallothioneins by spectroscopic, molecular biology, and molecular modeling techniques. Coord. Chem. Rev. 2002, 233:319-339.
29. Sun H., Li H., Sadler P.J. Chem. Rev. 1999, 99:2817-2842.
30. Petering D., Xiao J., Nyayapati S., Fulmer P., Antholine W. Oxidation Damage by Bleomycin, Adriamycin and Other Cytotoxic Agents that Require Iron or Copper 1999, 135-157. The Royal Society of Chemistry, Cambridge. N. Farrell (Ed.).
31. Claussen C.A., Long E.C. Chem. Rev. 1999, 99:2797-2816.
32. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., Paull K.D. Science 1997, 275:343-349.
33. Boyle F.T., Costello G.F. Chem. Soc. Rev. 1998, 27:251-261.
34. Rosenberg B. Platinum Complexes for the Treatment of Cancer. Why the Search goes on. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999, 3-30. Wiley-VCH, New York. B. Lippert (Ed.).
35. Lippert B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999, Wiley-VCH, New York.
36. Kelland L.R., Farrell N.P. Platinum-based Drugs in Cancer Therapy 2000, Humana Press Totawa, New Jersey.
37. Wong E., Giandomenico C.M. Chem. Rev. 1999, 99:2451-2466.
38. Weiss R.B., Christian M.C. Drugs 1993, 46:360-377.
39. Lebwohl D., Canetta R. Eur. J. Cancer 1998, 34:1522-1534.
40. O'Dwyer P.J., Johnson S.W., Hamilton T.C. Cisplatin and Its Analogues. Cancer Principles and Practice of Oncology 1997, 2:418-431. Lippincott-Raven, Philadelphia. 5th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
41. O'Dwyer P.J., Stevenson J.P., Johnson S.W. Clinical Status of Cisplatin, Carboplatin, and Other Platinum-based Antitumor Drugs. In Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999, 31-72. Wiley-VCH, New York. B. Lippert (Ed.).
42. Highley M.S., Calvert A.H. Clinical Experience with Cisplatin and Carboplatin 2000, 89-113. Humana Press, Totowa NJ. L.R. Kelland, N.P. Farrell (Eds.).
43. Christian M.C. Semin. Oncol. 1992, 19:720.
44. Lokich J., Anderson N. Ann. Oncol. 1998, 9:13-21.
45. Burcheranal J.H., Kalaher K., Dew K. Biochemie 1978, 60:961.
46. Macdonald J.S., Astrow A.B. Semin. Oncol. 2001, 28:30-40.
47. Pelley R.J. Curr. Oncol. Rep. 2001, 3:147-155.
48. Ruley H.E. Important Adv. Oncol. 1996, 10:37-56.
49. Eastman A. The Mechanism of Action of Cisplatin: From Adducts to Apoptosis. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999, 111-134. Wiley-VCH, Weinheim. B. Lippert (Ed.).
50. Gonzalez V.M., Fuertes M.A., Alonso C., Perez J.M. Mol. Pharmacol. 2001, 59:657-663.
51. Kartalou M., Essigmann J.M. Mutat. Res. 2001, 478:23-43.
52. Perez R.P. Eur. J. Cancer 1998, 34:1535-1542.
53. Kartalou M., Essigmann J.M. Mutat. Res. 2001, 478:1-21.
54. Harrap K.R., Jones M., Siracky J., Pollard L.A., Kelland L.R. Ann. Oncol. 1990, 1:65-76.
55. Loh S.Y., Mistry P., Kelland L.R., Abel G., Harrap K.R. Br. J. Cancer 1992, 66:1109-1115.
56. Berners-Price S.J., Appleton T.G. The Chemistry of Cisplatin in Aqueous Solution. Platinum-Based Drugs in Cancer Therapy 2000, Humana Press, Totowa, NJ. L.R. Kelland, N. Farrell (Eds.).
57. Miller S.E., House D.A. Inorg. Chim. Acta 1991, 187:125-132.
58. Berners-Price S.J., Sadler P.J. Coord. Chem. Rev. 1996, 151:1-40.
59. Appleton T.G., Hall J.R., Ralph S.F. Inorg. Chem. 1985, 24:4685-4693.
60. Kozelka J., Legendre F., Reeder F., Chottard J. Coord. Chem. Rev. 1999, 190-192:61-82.
61. Canovese L., Cattalini L., Chessa G., Tobe M.L.J. Chem. Soc. Dalton Trans. 1988, 2135-2140.
62. Esposito B.P., Najjar R. Coord. Chem. Rev. 2002, 232:137-150.
63. Ivanov A.I., Christodoulou J., Parkinson J.A., Barnham K.J., Tucker A., Woodrow J., Sadler P.J. J. Biol. Chem. 1998, 273:14721-14730.
64. Reedijk J. Chem. Rev. 1999, 99:2499-2510.
65. Djuran M.I., Lempers E.L.M., Reedijk J. Inorg. Chem. 1991, 30:2648-2652.
66. Appleton T.G., Connor J.W., Hall J.R., Prenzler P.D. Inorg. Chem. 1989, 28:2030-2037.
67. Murdoch P.d.S., Kratochwil N.A., Parkinson J.A., Patriarca M., Sadler P.J. Angew Chem., Int. Ed. Engl. 1999, 38:1949-2951.
68. Lempers E.L.M., Inagaki K., Reedijk J. Inorg. Chim. Acta 1988, 152:201-207.
69. Mitchell K.A., Streveler K.C., Jensen C.M. Inorg. Chem. 1993, 32:2608-2609.
70. Alden W.W., Repta A.J. Chem. Biol. Interact. 1984, 48:121-124.
71. Murdoch P.d.S., Ranford J.D., Sadler P.J., Berners-Price S.J. Inorg. Chem. 1993, 32:2249-2255.
72. Barnham K.J., Djuran M.I., Murdoch P.d.S., Ranford J.D., Sadler P.J. Inorg. Chem. 1996, 35:1065-1072.
73. Hambley T.W. J. Chem. Soc., Dalton Trans. 2001, 2711-2718.
74. Cohen S.M., Lippard S.J. Prog. Nucleic Acid Res. Mol. Biol. 2001, 67:93-130.
75. Brabec V. DNA Modifications by Antitumor Platinum and Ruthenium Compounds: Their Recognition and Repair 2002, 71:2-45. Academic Press, Amsterdam.
76. Takahara P.M., Rosenzweig A.C., Frederick C.A., Lippard S.J. Nature 1995, 377:649-652.
77. Gelasco A., Lippard S.J. Biochemistry 1998, 37:9230-9239.
78. Schwartz A., Marrot L., Leng M. Biochemistry 1989, 28:7975-7979.
79. Gelasco A., Lippard S.J. Anticancer Activity of Cisplatin and Related Complexes. Metallopharmaceuticals l: DNA Interactions 1999, 1:1-44. Springer-Verlag, Berlin. M.J. Clarke, P.J. Sadler (Eds.).
80. Marzilli L.G., Saad J.S., Kuklenyik Z., Keating K.A., Xu Y. J. Am. Chem. Soc. 2001, 123:2764-2770.
81. Spingler B., Whittington D.A., Lippard S.J. Inorg. Chem. 2001, 40:5596-5602.
82. Mani S., Graham M.A., Bregman D.B., Ivy P., Chaney S.G. Cancer Invest. 2002, 20:246-263.
83. Woynarowski J.M., Faivre S., Herzig M.C., Arnett B., Chapman W.G., Trevino A.V., Raymond E., Chaney S.G., Vaisman A., Varchenko M., Juniewicz P.E. Mol. Pharmacol. 2000, 58:920-927.
84. Coste F., Malinge J.M., Serre L., Shepard W., Roth M., Leng M., Zelwer C. Nucleic Acids Res. 1999, 27:1837-1846.
85. Coste F., Shepard W., Zelwer C. Acta Crystallogr. D 2002, 58:431-440.
86. Huang H., Zhu L., Reid B.R., Drobny G.P., Hopkins P.B. Science 1995, 270:1842-1845.
87. Paquet F., Perez C., Leng M., Lancelot G., Malinge J.M. J. Biomol. Struct. Dyn. 1996, 14:67-77.
88. Brabec V., Leng M. Proc. Natl. Acad. Sci. USA 1993, 90:5345-5349.
89. Chu G. J. Biol. Chem. 1994, 269:787-790.
90. Zlatanova J., Yaneva J., Leuba S.H. Faseb J. 1998, 12:791-799.
91. Patrick S.M., Turchi J.J. Biochemistry 1998, 37:8808-8815.
92. Thomas J.O. Biochem. Soc. Trans. 2001, 29:395-401.
93. Ohndorf U.M., Rould M.A., He Q., Pabo C.O., Lippard S.J. Nature 1999, 399:708-712.
94. He Q., Ohndorf U.M., Lippard S.J. Biochemistry 2000, 39:14426-14435.
95. Holford J., Sharp S.Y., Murrer B.A., Abrams M., Kelland L.R. Br. J. Cancer 1998, 77:366-373.
96. Raynaud F.I., Boxall F.E., Goddard P.M., Valenti M., Jones M., Murrer B.A., Abrams M., Kelland L.R. Clin. Cancer Res. 1997, 3:2063-2074.
97. Holford J., Raynaud F., Murrer B.A., Grimaldi K., Hartley J.A., Abrams M., Kelland L.R. Anticancer Drug Des. 1998, 13:1-18.
98. Chen Y., Guo Z., Parsons S., Sadler P.J. Chem. Eur. J. 1998, 4:672-676.
99. Chen Y., Parkinson J.A., Guo Z., Brown T., Sadler P.J. Angew Chem., Int. Ed. 1999, 38:2060-2063.
100. Trigo J.M., Beale P., Judson I.R., Raynaud F., Rees C., Milan D., Wolf L., Walker R., Hanwell J., Giandomenico C. ASCO 1999, 648.
101. Mellish K.J., Barnard C.F., Murrer B.A., Kelland L.R. Int. J. Cancer 1995, 62:717-723.
102. Hall M.D., Hambley T.W. Coord. Chem. Rev. 2002, 232:49-67.
103. Lemma K., Sargeson A.M., Elding L.I. J. Chem. Soc., Dalton Trans. 2000, 1167-1172.
104. Lemma K., Berglund J., Farrell N., Elding L.I. J. Biol. Inorg. Chem. 2000, 5:300-306.
105. Giandomenico C.M., Abrams M.J., Murrer B.A., Vollano J.F., Rheinheimer M.I., Wyer S.B., Bossard G.E., Higgins J.D. Inorg. Chem. 1998, 34:1015-1021.
106. Carr J.L., Tingle M.D., McKeage M.J. Cancer Chemother. Pharmacol. 2002, 50:9-15.
107. Raynaud F.I., Mistry P., Donaghue A., Poon G.K., Kelland L.R., Barnard C.F., Murrer B.A., Harrap K.R. Cancer Chemother. Pharmacol. 1996, 38:155-162.
108. Hartwig J.F., Lippard S.J. J. Am. Chem. Soc. 1992, 114:5646-5654.
109. Kurata T., Tamura T., Sasaki Y., Fujii H., Negoro S., Fukuoka M., Saijo N. Jpn J. Clin. Oncol. 2000, 30:377-384.
110. Kelland L.R. Exp. Opin. Invest. Drugs 2000, 9:1373-1382.
111. Farrell N., Qu Y., Hacker M.P. J. Med. Chem. 1990, 33:2179-2184.
112. Farrell N. Comm. Inorg. Chem. 1995, 16:373-389.
113. Farrell N. DNA Binding of Dinuclear Platinum Complexes. Advances in DNA Sequence Specific Agents 1996, 2:187-216. JAI Press. L.H. Hurley, J.B. Chaires (Eds.).
114. Farrell N. Cancer Invest. 1993, 11:578-589.
115. Qu Y., Rauter H., Soares Fontes A.P., Bandarage R., Kelland L.R., Farrell N. J. Med. Chem. 2000, 43:3189-3192.
116. Farrell N.P., Qu Y., Bierbach U., Valsecchi M., Menta E. Structure-activity Relationships within Di- and Trinuclear Platinum Phase I Clinical Agents. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999, 479-496. Verlag. B. Lippert (Ed.).
117. Farrell N., Spinelli S. Dinuclear and Trinuclear Platinum Anticancer Agents. Uses of Inorganic Chemistry in Medicine 1999, 124-134. The Royal Society of Chemistry, Cambridge. N. Farrell (Ed.).
118. Farrell N.P. Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm. Platinum-Based Drugs in Cancer Therapy 2000, 321-338. Humana Press. L.R. Kelland, N.P. Farrell (Eds.).
119. Qu Y., Appleton T.G., Hoeschele J.D., Farrell N. Inorg. Chem. 1993, 32:2591.
120. Manzotti C., Pratesi G., Menta E., Di Domenico R., Cavalletti E., Fiebig H.H., Kelland L.R., Farrell N., Polizzi D., Supino R., Pezzoni G., Zunino F. Clin. Cancer Res. 2000, 6:2626-2634.
121. Pratesi G., Perego P., Polizzi D., Righetti S.C., Supino R., Caserini C., Manzotti C., Giuliani F.C., Pezzoni G., Tognella S., Spinelli S., Farrell N., Zunino F. Br. J. Cancer 1999, 80:1912-1919.
122. Perego P., Caserini C., Gatti L., Carenini N., Romanelli S., Supino R., Colangelo D., Viano I., Leone R., Spinelli S., Pezzoni G., Manzotti C., Farrell N., Zunino F. Mol. Pharmacol. 1999, 55:528-534.
123. Orlandi L., Colella G., Bearzatto A., Abolafio G., Manzotti C., Daidone M.G., Zaffaroni N. Eur. J. Cancer 2001, 37:649-659.
124. Calvert P.M., Highley M.S., Hughes A.N., Plummer E.R., Azzabi A.S.T., Verrill M.W., Camboni M.G., Verdi E., Bernareggi A., Zucchetti M., Robinson A.M., Carmichael J., Calvert A.H. Clin. Cancer Res. 1999, 5:3796s.
125. Sessa C., Capri G., Gianni L., Peccatori F., Grasselli G., Bauer J., Zucchetti M., Vigano L., Gatti A., Minoia C., Liati P., Van den Bosch S., Bernareggi A., Camboni G., Marsoni S. Ann. Oncol. 2000, 11:977-983.
126. Gourley C., Cassidy J., Bisset D., Camboni G., Boyle D., Joddrell D. Proc. AACR 2002, 2760.
127. Calvert A.H., Thomas H., Colombo N., Gore M., Earl H., Sena L., Camboni G., Liati P., Sessa C. European Journal of Cancer 2001, 37(supp6).
128. Phase II Clinical Study of BBR3464, a Novel, Bifunctional Platinum Analogue, in Patients with Advanced Ovarian Cancer 2001, Poster Discussion 965.
129. Scagliotti G., Crino L., de Marinis F., Tonato M., Selvaggi G., Massoni F., Maestri A., Gatti B., Camboni G. European Journal of Cancer 2001, 37 (Supp6) Poster 182. Phase II Trial of BBR3464, a Novel, Bifunctional Platinum Analogue, in Advanced but Favourable Out-come, Non Small Cell Lung Cancer Patients 2001.
130. Roberts J.D., Peroutka J., Farrell N. J. Inorg. Biochem. 1999, 77:51-57.
131. Perego P., Gatti L., Caserini C., Supino R., Colangelo D., Leone R., Spinelli S., Farrell N., Zunino F. J. Inorg. Biochem. 1999, 77:59-64.
132. Guo Z., Chen Y., Zang E., Sadler P.J. J. Chem. Soc., Dalton Trans. 1997, 4107-4111.
133. Davies M.S., Cox J., Berners-Price S., Barklage W., Qu Y., Farrell N. Inorg. Chem. 2000, 39:1710-1715.
134. Davies M.S., Thomas D.S., Hegmans A., Berners-Price S.J., Farrell N. Inorg. Chem. 2002, 41:1101-1109.
135. McGregor T.D., Hegmans A., Kasparkova J., Neplechova K., Novakova O., Penazova H., Vrana O., Brabec V., Farrell N. J. Biol. Inorg. Chem. 2002, 7:397-404.
136. Brabec V., Kasparkova J., Vrana O., Novakova O., Cox J.W., Qu Y., Farrell N. Biochemistry 1999, 38:6781-6790.
137. Johnson A., Qu Y., Van Houten B., Farrell N. Nucleic Acids Res. 1992, 20:1697-1703.
138. Wu P.K., Kharatishvili M., Qu Y., Farrell N. J. Inorg. Biochem. 1996, 63:9-18.
139. McGregor T.D., Balcarova Z., Qu Y., Tran M.C., Zaludova R., Brabec V., Farrell N. J. Inorg. Biochem. 1999, 77:43-46.
140. McGregor T.D., Bousfield W., Qu Y., Farrell N. J. Inorg. Biochem. 2002, 91:212-219.
141. Walker G.T., Stone M.P., Krugh T.R. Biochemistry 1985, 24:7462-7471.
142. Kim Y., Geiger J.H., Hahn S., Sigler P.B. Nature 1993, 365:512-520.
143. Herbert A., Rich A. J. Biol. Chem. 1996, 271:11595-11598.
144. Gohlke C., Murchie A.I., Lilley D.M., Clegg R.M. Proc. Natl. Acad. Sci. USA 1994, 91:11660-11664.
145. Kloster M.B., Hannis J.C., Muddiman D.C., Farrell N. Biochemistry 1999, 38:14731-14737.
146. Cox J.W., Berners-Price S.J., Davies M.S., Qu Y., Farrell N. J. Am. Chem. Soc. 2001, 123:1316-1326.
147. Davies, M. S.; Thomas, D. S.; Hegmans, A.; Berners-Price, S. J.; Qu,Y.; Farrell, N. A Comparison of the kinetics of formation of 1,4-interstrand crosslinks by the trinuclear clinical agent BBR3464: Preassociation and evidence of conformational flexibility J. Am. Chem. Soc. submitted for publication.
148. Wang Y., Farrell N., Burgess J.D. J. Am. Chem. Soc. 2001, 123:5576-5577.
149. Qu Y., Scarsdale N.J., Tran M.C., Farrell N. Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn-orientation of adenine bases outside the binding sites. J Biol Inorg Chem. 2003, 8:19-28.
150. Rajski S.R., Williams R.M. Chem. Rev. 1998, 98:2723-2796.
151. Thompson A.S., Hurley L.H. J. Mol. Biol. 1995, 252:86-101.
152. Seaman F.C., Chu J., Hurley L. J. Am. Chem. Soc. 1996, 118:5383-5395.
153. Qu Y., Bloemink M.J., Reedijk J., Hambley T.W., Farrell N. J. Am. Chem. Soc. 1996, 118:9307.
154. Kasparkova J., Novakova O., Vrana O., Farrell N., Brabec V. Biochemistry 1999, 38:10997-11005.
155. Kasparkova J., Mellish K.J., Qu Y., Brabec V., Farrell N. Biochemistry 1996, 35:16705-16713.
156. Kasparkova J., Farrell N., Brabec V. J. Biol. Chem. 2000, 275:15789-15798.
157. Zehnulova J., Kasparkova J., Farrell N., Brabec V. J. Biol. Chem. 2001, 276:22191-22199.
158. Kasparkova J., Zehnulova J., Farrell N., Brabec V. DNA interstrand crosslinks of novel antitumor trinuclear platinum complex BBR. Conformation, recognition by HMG-domain proteins and nucleotide excision repair. J Biol Chem. 2002, 277:48076-48086.
159. Sancar A. Annu. Rev. Biochem. 1996, 65:43-81.
160. Servidei T., Ferlini C., Riccardi A., Meco D., Scambia G., Segni G., Manzotti C., Riccardi R. Eur. J. Cancer 2001, 37:930-938.
161. Wheate N.J., Webster L.K., Brodie C.R., Collins J.G. Anticancer Drug Des. 2000, 15:313-322.
162. Komeda S., Lutz M., Spek A.L., Chikuma M., Reedijk J. Inorg. Chem. 2000, 39:4230-4236.
163. Komeda S., Lutz M., Spek A.L., Yamanaka Y., Sato T., Chikuma M., Reedijk J. J. Am. Chem. Soc. 2002, 124:4738-4746.
164. Farrell N., Ha T.T., Souchard J.P., Wimmer F.L., Cros S., Johnson N.P. J. Med. Chem. 1989, 32:2240-2241.
165. Van Beusichem M., Farrell N. Inorg. Chem. 1992, 31:634.
166. Farrell N., Kelland L.R., Roberts J.D., Van Beusichem M. Cancer Res. 1992, 52:5065-5072.
167. Natile G., Coluccia M. Trans-platinum Compounds in Cancer Therapy: A Largely Unexplored Strategy for Identifying Novel Antitumor Platinum Drugs. Metallopharmaceuticals l: DNA Interactions 1999, 1:73-98. Springer-Verlag, Berlin. M.J. Clarke, P.J. Sadler (Eds.).
168. Natile G., Coluccia M. Coord Chem. Rev. 2001, 216:383-410.
169. Perez J.M., Montero E.I., Gonzalez A.M., Solans X., Font-Bardia M., Fuertes M.A., Alonso C., Navarro-Ranninger C. J. Med. Chem. 2000, 43:2411-2418.
170. Montero E.I., Diaz S., Gonzalez-Vadillo A.M., Perez J.M., Alonso C., Navarro-Ranninger C. J. Med. Chem. 1999, 42:4264-4268.
171. Khazanov E., Barenholz Y., Gibson D., Najraeh Y. Novel apoptosis-including trans-platinum piperidine and piperazine derivatives: Synthesis and biological characterization. J. Med. Chem. 2002, 45:5189-5195.
172. Farrell N. Met. Ions Biol. Sys. 1996, 32:603-634.
173. Bierbach U., Sabat M., Farrell N. Inorg. Chem. 2000, 39:1882-1890.
174. Zou Y., Van Houten B., Farrell N. Biochemistry 1993, 32:9632-9638.
175. Brabec V., Neplechova K., Kasparkova J., Farrell N. J. Biol. Inorg. Chem. 2000, 5:364-368.
176. Bierbach U., Qu Y., Hambley T.W., Peroutka J., Nguyen H.L., Doedee M., Farrell N. Inorg. Chem. 1999, 38:3535-3542.
177. Bierbach U., Farrell N. Inorg. Chem. 1997, 36:3657-3665.
178. Bierbach U., Farrell N. J. Biol. Inorg. Chem. 1998, 3:570.
179. Zaludova R., Zakovska A., Kasparkova J., Balcarova Z., Vrana O., Coluccia M., Natile G., Brabec V. Mol. Pharmacol. 1997, 52:354-361.
180. Clarke M.J., Zhu F., Frasca D.R. Chem. Rev. 1999, 99:2511-2534.
181. Clarke M.J. Ruthenium Chemistry Pertaining to the Design of Anticancer Agents 1989, 10:25-40. Progress in Clinical Biochemistry and Medicine; Springer-Verlag, Berlin.
182. Frasca D.R., Clarke M.J. J. Am. Chem. Soc. 1999, 121:8523-8532.
183. Zhao M., Clarke M.J. J. Biol. Inorg. Chem. 1999, 4:318-324.
184. LaChance-Galang K., Zhao M., Clarke M.J. Inorg. Chem. 1996, 35:6021-6026.
185. Keppler B.K., Friesen C., Moritz H.G., Vongerichten H., Vogel E. Struct. Bonding 1991, 78:97-127.
186. Pieper T., Borsky K., Keppler B.K. Non-platinum Antitumor Compounds. Metallopharmacecuticals l: DNA Interactions 1999, 1:171-199. Springer-Verlag, Berlin. M.J. Clarke, P.J. Sadler (Eds.).
187. Kratz F., Hartmann M., Keppler B., Messori L. J. Biol. Chem. 1994, 269:2581-2588.
188. Sava G., Alessio E., Bergamo A., Mestroni G. Sulfoxide Ruthenium Complexes: Non Toxic Tools for the Selective Treatment of Solid Tumor Metastases. Metallopharmaceuticals l: DNA Interactions 1999, 1:143-170. Springer-Verlag, Berlin. M.J. Clarke, P.J. Sadler (Eds.).
189. Sanna B., Debidda M., Pintus G., Tadolini B., Posadino A.M., Bennardini F., Sava G., Ventura C. Arch. Biochem. Biophys. 2002, 403:209-218.
190. Cherrington J.M., Strawn L.M., Shawver L.K. Adv. Cancer Res. 2000, 79:1-38.
191. Sava G., Clerici K., Capozzi I., Cocchietto M., Gagliardi R., Alessio E., Mestroni G., Perbellini A. Anticancer Drugs 1999, 10:129-138.
192. Bergamo A., Gagliardi R., Scarcia V., Furlani A., Alessio E., Mestroni G., Sava G. J. Pharmacol. Exp. Ther. 1999, 289:559-564.
193. Zorzet S., Bergamo A., Cocchietto M., Sorc A., Gava B., Alessio E., Iengo E., Sava G. J. Pharmacol. Exp. Ther. 2000, 295:927-933.
194. Sava G., Bergamo A., Zorzet S., Gava B., Casarsa C., Cocchietto M., Furlani A., Scarcia V., Serli B., Iengo E., Alessio E., Mestroni G. Eur. J. Cancer 2002, 38:427-435.
195. Gopal Y.N., Jayaraju D., Kondapi A.K. Biochemistry 1999, 38:4382-4388.
196. Chen H., Parkinson J.A., Parsons S., Coxall R.A., Gould R.O., Sadler P.J. J. Am. Chem. Soc. 2002, 124:3064-3082.
197. Morris R.E., Aird R.E., Murdoch Pdel S., Chen H., Cummings J., Hughes N.D., Parsons S., Parkin A., Boyd G., Jodrell D.I., Sadler P.J. J. Med. Chem. 2001, 44:3616-3621.
198. Antman K.H. Oncologist 2001, 6:1-2.
199. Waxman S., Anderson K.C. Oncologist 2001, 6:3-10.
200. Shen Z.X., Chen G.Q., Ni J.H., Li X.S., Xiong S.M., Qiu Q.Y., Zhu J., Tang W., Sun G.L., Yang K.Q., Chen Y., Zhou L., Fang Z.W., Wang Y.T., Ma J., Zhang P., Zhang T.D., Chen S.J., Chen Z., Wang Z.Y. Blood 1997, 89:3354-3360.
201. Novick S.C., Warrell R.P. Semin. Oncol. 2000, 27:495-501.
202. Rust D.M., Soignet S.L. Oncologist 2001, 6:29-32.
203. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Cancer Res. 2002, 62:3893-3903.
204. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., Waxman S. Blood 1999, 94:2102-2111.
205. Dai J., Weinberg R.S., Waxman S., Jing Y. Blood 1999, 93:268-277.
206. Yang C.H., Kuo M.L., Chen J.C., Chen Y.C. Br. J. Cancer 1999, 81:796-799.
207. Zhang T.D., Chen G.Q., Wang Z.G., Wang Z.Y., Chen S.J., Chen Z. Oncogene 2001, 20:7146-7153.
208. Kroemer G., de The H. J. Natl. Cancer Inst. 1999, 91:743-745.
209. Preston T.J., Abadi A., Wilson L., Singh G. Adv. Drug Deliv. Rev. 2001, 49:45-61.
210. Costantini P., Jacotot E., Decaudin D., Kroemer G. J. Natl. Cancer Inst. 2000, 92:1042-1053.
211. Koya K., Li Y., Wang H., Ukai T., Tatsuta N., Kawakami M., Shishido L.B., Chen Cancer Res. 1996, 56:538-543.
212. McKeage M.J., Maharaj L., Berners-Price S.J. Coord. Chem. Rev. 2002, 232:127-135.
213. Berners-Price S.J., Bowen R.J., Galettis P., Healy P.C., McKeage M.J. Coord. Chem. Rev. 1999, 185-186:823-836.
214. Berners-Price S., Jarrett P., Sadler P. Inorg. Chem. 1987, 26:3074-3077.
215. Shaw C.F. Chem. Rev. 1999, 99:2589-2600.
216. Berners-Price S.J., Girard G.R., Hill D.T., Sutton B.M., Jarrett P.S., Faucette L.F., Johnson R.K., Mirabelli C.K., Sadler P.J. J. Med. Chem. 1990, 33:1386-1392.
217. McKeage M.J., Berners-Price S.J., Galettis P., Bowen R.J., Brouwer W., Ding L., Zhuang L., Baguley B.C. Cancer Chemother. Pharmacol. 2000, 46:343-350.
218. Berners-Price S., Bowen R., Hambley T., Healy P. J. Chem. Soc., Dalton Trans. 1999, 8:1337-1346.
219. Riley D.P. Chem. Rev. 1999, 99:2573-2588.
220. McCord J.M., Fridovich I. J. Biol. Chem. 1969, 244:6049-6055.
221. Kramer R. Angew Chem., Int. Ed. 2000, 39:4469-4470.
222. Weiss R., Riley D. Therapeutic Aspects of Manganese(II)-based Superoxide Dismutase Mimics. Uses of Inorganic Chemistry in Medicine 1999, 77-92. The Royal Society of Chemistry, Cambridge. N. Farrell (Ed.).
223. Doctrow S.R., Huffman K., Marcus C.B., Musleh W., Bruce A., Baudry M., Malfroy B. Adv. Pharmacol. 1997, 38:247-269.
224. Melov S., Ravenscroft J., Malik S., Gill M.S., Walker D.W., Clayton P.E., Wallace D.C., Malfroy B., Doctrow S.R., Lithgow G.J. Science 2000, 289:1567-1569.
225. Salvemini D., Wang Z.Q., Zweier J.L., Samouilov A., Macarthur H., Misko T.P., Currie M.G., Cuzzocrea S., Sikorski J.A., Riley D.P. Science 1999, 286:304-306.
226. Aston K., Rath N., Naik A., Slomczynska U., Schall O.F., Riley D.P. Inorg. Chem. 2001, 40:1779-1789.
227. Melendez E. Crit. Rev. Oncol. Hematol. 2002, 42:309-315.
228. Comba P., Jakob H., Nuber B., Keppler B.K. Inorg. Chem. 1994, 33:3396-3400.
229. Schilling T., Keppler K.B., Heim M.E., Niebch G., Dietzfelbinger H., Rastetter J., Hanauske A.R. Invest. New Drugs 1996, 13:327-332.
230. Christodoulou C.V., Ferry D.R., Fyfe D.W., Young A., Doran J., Sheehan T.M., Eliopoulos A., Hale K., Baumgart J., Sass G., Kerr D.J. J. Clin. Oncol. 1998, 16:2761-2769.
231. Korfel A., Scheulen M.E., Schmoll H.J., Grundel O., Harstrick A., Knoche M., Fels L.M., Skorzec M., Bach F., Baumgart J., Sass G., Seeber S., Thiel E., Berdel W.E. Clin. Cancer Res. 1998, 4:2701-2708.
232. Lummen G., Sperling H., Luboldt H., Otto T., Rubben H. Cancer Chemother. Pharmacol. 1998, 42:415-417.
233. Harding M.M., Mokdsi G. Curr. Med. Chem. 2000, 7:1289-1303.
234. Kuo L.Y., Liu A.H., Marks T.J. Met. Ions Biol. Syst. 1996, 33:53-85.
235. Harding M.M., Mokdsi G., Lucas W. Inorg. Chem. 1998, 37:2432-2437.
236. Sun H., Li H., Weir R.A., Sadler P.J. Angew Chem., Int. Ed. Engl. 1998, 37:1577-1579.
237. Apseloff G. Am. J. Ther. 1999, 6:327-339.
238. Webster L.K., Olver I.N., Stokes K.H., Sephton R.G., Hillcoat B.L., Bishop J.F. Cancer Chemother. Pharmacol. 2000, 45:55-58.
239. Senderowicz A.M., Reid R., Headlee D., Abornathy T., Horti J., Lush R.M., Reed E., Figg W.D., Sausville E.A. Urol. Int. 1999, 63:120-125.
240. Collery P., Lechenault F., Cazabat A., Juvin E., Khassanova L., Evangelou A., Keppler B. Anticancer Res. 2000, 20:955-958.
241. Arion V.B., Jakupec M.A., Galanski M., Unfried P., Keppler B.K. J. Inorg. Biochem. 2002, 91:298-305.
242. Knorr G.M., Chitambar C.R. Anticancer Res. 1998, 18:1733-1737.
243. Grier N. Mercurials-Inorganic and Organic. Mercurials-Inorganic and Organics (Disinfection, Sterilization and Preservation.) 1983, 346-374. Lea and Fabringer. S.S. Block (Ed.).
244. Grier N. Silver and Its Compounds. Mercurials-Inorganic and Organics (Disinfection, Sterilization and Preservation.) 1983, 375-389. Lea and Fabringer. S.S. Block (Ed.).
245. Gupta A., Matsui K., Lo J.F., Silver S. Nat. Med. 1999, 5:183-188.
246. Clement J.L., Jarrett P.S. Met. Based Drugs 1994, 1:467-782.
247. Briand G.G., Burford N. Chem. Rev. 1999, 99:2601-2658.
248. Reglinski J. Chemistry of Arsenic, Antimony, and Bismuth 1998, Blackie Academic & Professional, London.
249. Briand N., Burford Adv. Inorg. Chem. 2002, 50:285-357.
250. Asato E., Driessen W.L., de Graaff R.A.G., Hulsbergen F.B., Reedijk J. Inorg. Chem. 1991, 30:4210-4218.
251. Asato E., Katsura K., Mikuriya M., Fujii T., Reedijk J. Inorg. Chem. 1993, 32:5322-5329.
252. Asato E., Katsura K., Mikuriya M., Turpeinen U., Mutikainen I., Reedijk J. Inorg. Chem. 1995, 34:2447-2454.
253. Sadler P.J., Li H., Sun H. Coord. Chem. Rev. 1999, 185-186:689-709.
254. Sadler P.J., Sun H. J. Chem. Soc., Dalton Trans. 1995, 1395-1401.
255. Burford N., Eelman M.D., Cameron T.S. Chem. Commun. (Camb) 2002, 1402-1403.
256. Whitmire K. J. Chem. Soc. Chem. Commun. 2002, 2834-2835.
257. Sadler P.J., Sun H.Z., Li H.Y. Chem. Eur. J. 1996, 2:701-708.
258. Sun H., Li H., Mason A.B., Woodworth R.C., Sadler P.J. Biochem. J. 1999, 337:105-111.
259. Navarro M., Perez H., Sanchez-Delgado R.A. J. Med. Chem. 1997, 40:1937-1939.
260. Navarro M., Cisneros-Fajardo E.J., Lehmann T., Sanchez-Delgado R.A., Atencio R., Silva P., Lira R., Urbina J.A. Inorg. Chem. 2001, 40:6879-6884.
261. Sanchez-Delgado R.A., Lazardi K., Rincon L., Urbina J.A. J. Med. Chem. 1993, 36:2041-2043.
262. Sanchez-Delgado R.A., Navarro M., Perez H., Urbina J.A. J. Med. Chem. 1996, 39:1095-1099.
263. Birch N. Biomedical Uses of Lithium 1999, 11-21. The Royal Society of Chemistry, Cambridge. N. Farrell (Ed.).
264. Birch N.J. Chem. Rev. 1999, 99:2659-2682.
265. Orvig C., Thompson K.H., Battell M., McNeill J.H. Metal Ions in Biological Systems: Vanadium and its Role in Life. Metal Ions in Biological Systems, Sigel 1995, 31:575. Marcel Dekker, New York. H. Sigel, A. Sigel (Eds.).
266. Blondel O., Simon J., Chevalier B., Portha B. Am. J. Physiol. 1990, 258:E459-E467.
267. Thompson K.H., McNeill J.H., Orvig C. Chem. Rev. 1999, 99:2561-2572.
268. Orvig C., Thompson K., Cam M., McNeil J. Vanadium Compounds as Possible Insulin Modifiers. Uses of Inorganic Chemistry in Medicine 1999, 93-108. The Royal Society of Chemistry, Cambridge. N. Farrell (Ed.).
269. Huyer G., Liu S., Kelly J., Moffat J., Payette P., Kennedy B., Tsaprailis G., Gresser M.J., Ramachandran C. J. Biol. Chem. 1997, 272:843-851.
270. Elberg G., He Z., Li J., Sekar N., Shechter Y. Diabetes 1997, 46:1684-1690.
271. Shaw C. Gold Complexes with Anti-arthritic, Anti-tumour and Anti-HIV Activity. Uses of Inorganic Chemistry in Medicine 1999, 26-57. The Royal Society of Chemistry, Cambridge. N. Farrell (Ed.).
272. Snyder R.M., Mirabelli C.K., Crooke S.T. Semin. Arthritis Rheum. 1987, 17:71-80.
273. Rudkowski R., Graham G.G., Champion G.D., Ziegler J.B. Biochem. Pharmacol. 1990, 39:1687-1695.
274. Butler A., Rhodes P. Nitric Oxide in Physiology and Medicine. Uses of Inorganic Chemistry in Medicine 1999, 58-76. The Royal Society of Chemistry, Cambridge. N. Farrell (Ed.).
275. Clarke M.J., Gaul J.B. Struct. Bonding 1993, 81:147-181.
276. Butler A.R., Williams D.L.H. Chem. Soc. Rev. 1993, 22:233-241.
277. Groves J.T. Curr. Opin. Chem. Biol. 1999, 3:226-235.
278. Shimanovich R., Groves J.T. Arch. Biochem. Biophys. 2001, 387:307-317.
279. Shimanovich R., Hannah S., Lynch V., Gerasimchuk N., Mody T.D., Magda D., Sessler J., Groves J.T. J. Am. Chem. Soc. 2001, 123:3613-3614.
280. Hergesell O., Ritz E. Kidney Int. 1999, 73:S42-S45.
281. Hutchison A.J. Perit. Dial. Int. 1999, 19:S408-S412.
282. Hergesell O., Ritz E. Phosphate binders on iron basis: a new perspective?. Kidney Int. Suppl. 1999, 73:S42-45.